PR95041

MADRID, March 17, 2022 /PRNewswire=KYODO JBN/ --

    KeyZell, a Spanish biotechnology company in the development phase of

digital cancer treatments and tools, has just opened a private financing round

which expects to achieve 5 million euros to boost its projects and consolidate

itself as one of the biotech start-ups with the greatest international

projection.

    KeyZell launches this new round of private investment to conduct a human

clinical trial with one of its innovative cancer treatments, based on Dr. Nabil

Hajji's research on cellular apoptosis induced by cell receptor blockage, as

well as to improve its precision medicine Artificial Intelligence system that

aims to be the future of cancer medicine, thanks to an algorithm that proposes

the most appropriate personalized treatment for each patient depending on the

unique characteristics of each person and type of cancer.

    KeyZell has already generated great interest from both national private

investors and North American investment funds and has successfully closed a

preliminary round of 450,000 euros, 50% above expectations. Among its investors

are professional brokers as well as Spanish and Mexican businessmen.

    "We created KeyZell with the objective of developing new cancer solutions

and tools that can help both medical professionals and patients in their fight

against this disease. This financing round will allow us to achieve our

ambitious objective," says Jose del Corral, company CEO.

    The company is committed to blockchain technology, implementing

improvements on its AI-based tool and thus reinforcing this through clinical

trials. Keyzell plans to finance the clinical trial in Australia while in

negotiations with a strategic partner to carry out another trial in Mexico. In

addition, working on the structures to carry out regulatory processes in

Europe, United States, United Kingdom, Thailand, South Africa, Morocco and

Canada.

    Keyzell has the pleasure of having Dr. Nabil Hajji among its founders who

has led the research with collaborators from University of Seville and Harvard

University, where they have discovered a new treatment which for the first

time, after more than twenty years without advances in glioblastoma research,

has succeeded in eliminating the most aggressive brain cancer, glioblastoma.

    Media Contact:

    Inés Martínez

    imartinez@tinkle.es

    +34 661 750 597

    Source: KeyZell